A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Vertex Study Number: VX18-445-113

A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Vertex Study Number: VX18-445-113

  • Clinical Trial Information

    Trial Contact: Beltran, Yajira; Tilme, Linda

    Trial Phone: 321.841.7619 ; 321.843.5278

  • IRB No: 19.200.06

    Protocol Abbrev: VX18-445-113

    Principal Investigator: Luis Antonio Faverio, MD

    Phase: Drug: Phase III

    Age Group: Adult;Pediatric

    Secondary Protocol No: VX18-445-113

    Treatment: VX-445/TEZ/IVA

    Therapies Involved: Medication

    ClinicalTrials.gov ID: NCT03525574

  • Key Eligibility

    Completed study drug treatment in a parent study; or had study drug interruption(s) in a parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study.